[{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts","type":"changed","fields":[{"field":"summary","before":"\"Radioligand therapy kills by DNA damage, so blocking repair should amplify it. Early-phase studies combine 177Lu-PSMA with olaparib in prostate cancer and 177Lu-DOTATATE with PARP inhibitors in neuroendocrine tumours...","after":"\"Radioligand therapy kills by DNA damage, so blocking repair should amplify it. Early-phase studies combine 177Lu-PSMA with olaparib in prostate cancer and 177Lu-DOTATATE with PARP inhibitors in neuroendocrine tumours..."}]},{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"sections"},{"field":"status"},{"field":"asOf"},{"field":"tldr"},{"field":"summary"},{"field":"principle"},{"field":"strengths"},{"field":"limitations"},{"field":"technologies"},{"field":"targets"},{"field":"cancers"},{"field":"tags"},{"field":"links"}]}]